{'fraction_non_alphanumeric': 0.012048192771084338, 'fraction_numerical': 0.007228915662650603, 'mean_word_length': 5.5, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Biosimilars in rheumatic diseases

Although biosimilars have been introduced to the market for almost two decades, their comparison to biologics is still subject to debate. With more than 400 million days of treatment, their concept has been successfully proven. Many studies support the fact that there is no significant difference between biologics and biosimilars when assessing their respective safety features.